

Henry Ford Health

Henry Ford Health Scholarly Commons

Hematology/Oncology Meeting Abstracts

Hematology-Oncology

2-1-2023

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation-ECOG-ACRIN EA2192

Kim A. Reiss

Sung C. Hong

Anup Kasi

Eileen M. O'Reilly

Shishir K. Maithel

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts

Authors

Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, and Peter J. O'Dwyer

TPS763

Trials in Progress Poster Session

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic *BRCA1*, *BRCA2* or *PALB2* mutation—ECOG-ACRIN EA2192.

Kim Anna Reiss, Sung Chul Hong, Anup Kasi, Eileen Mary O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J Klemper, Susan M. Domchek, Paul J. Catalano, E. Gabriela Chiorean, Philip Agop Philip, Peter J. O'Dwyer; Abramson Cancer Center, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; University of Kansas Medical Center, Westwood, KS; Memorial Sloan Kettering Cancer Center, New York, NY; Winship Cancer Institute, Emory University, Atlanta, GA; ThedaCare Regional Medical Center, Appleton, WI; City of Hope National Medical Center, Duarte, CA; Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel; Johns Hopkins University School of Medicine, Washington, DC; Massachusetts General Hospital, Boston, MA; University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA; University of Washington, Seattle, WA; Henry Ford Cancer Institute, Detroit, MI; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Background: A meaningful subset of PDAC is characterized by a homologous recombination deficiency (HRD). The most well-defined patients within this group are those with pathogenic variants in *BRCA1*, *BRCA2* and *PALB2*. In the metastatic setting, PARP inhibitor maintenance provides a progression-free survival benefit after a period of platinum based chemotherapy^{1,2}, but the role of PARP inhibitors in the curative intent setting is undefined. The OlympiA study established one year of olaparib as the standard of care for patients with *BRCA*-related, early stage breast cancer who completed all other curative-intent treatment³. Therefore, we have designed a randomized, phase II double-blind study of one year of olaparib vs placebo in patients with pancreatic cancer and a germline or somatic variant in *BRCA* or *PALB2* who have completed all curative intent therapy. **Methods:** We have enrolled and treated 23 of 152 planned patients on study NCT 04858334/EA2192. Eligibility criteria include: a pathogenic germline or somatic variant in *BRCA1*, *BRCA2* or *PALB2* as determined by local laboratory (central review required); completion of curative-intent resection and \geq three months of multi-agent chemotherapy; no evidence of recurrent disease. At enrollment, patients must be within 12 weeks of their last anti-cancer intervention. Patients are randomized 2:1 to receive oral olaparib 300 mg twice daily or placebo for 12 28-day cycles. The primary endpoint is relapse-free survival. Overall survival is a secondary endpoint. Tumor tissue, fecal material (for microbiome analysis) and serial ctDNA samples are being collected. 1. Golan T, Locker GY, Kindler HL: *N Engl J Med* 381:1492-1493, 2019. 2. Reiss KA, Mick R, O'Hara MH, et al: *J Clin Oncol* 39:2497-2505, 2021. 3. Tutt ANJ, Garber JE, Geyer CE, Jr.: *N Engl J Med* 385:1440, 2021. Clinical trial information: NCT04858334. Research Sponsor: U.S. National Institutes of Health, PANCAN.